Cargando…

Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia

Muscle protein degradation is thought to play a major role in muscle atrophy in cancer cachexia. To investigate the importance of the ubiquitin-proteasome pathway, which has been suggested to be the main degradative pathway mediating progressive protein loss in cachexia, the expression of mRNA for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Khal, J, Wyke, S M, Russell, S T, Hine, A V, Tisdale, M J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361629/
https://www.ncbi.nlm.nih.gov/pubmed/16160695
http://dx.doi.org/10.1038/sj.bjc.6602780
_version_ 1782153260798312448
author Khal, J
Wyke, S M
Russell, S T
Hine, A V
Tisdale, M J
author_facet Khal, J
Wyke, S M
Russell, S T
Hine, A V
Tisdale, M J
author_sort Khal, J
collection PubMed
description Muscle protein degradation is thought to play a major role in muscle atrophy in cancer cachexia. To investigate the importance of the ubiquitin-proteasome pathway, which has been suggested to be the main degradative pathway mediating progressive protein loss in cachexia, the expression of mRNA for proteasome subunits C2 and C5 as well as the ubiquitin-conjugating enzyme, E2(14k), has been determined in gastrocnemius and pectoral muscles of mice bearing the MAC16 adenocarcinoma, using competitive quantitative reverse transcriptase polymerase chain reaction. Protein levels of proteasome subunits and E2(14k) were determined by immunoblotting, to ensure changes in mRNA were reflected in changes in protein expression. Muscle weights correlated linearly with weight loss during the course of the study. There was a good correlation between expression of C2 and E2(14k) mRNA and protein levels in gastrocnemius muscle with increases of 6–8-fold for C2 and two-fold for E2(14k) between 12 and 20% weight loss, followed by a decrease in expression at weight losses of 25–27%, although loss of muscle protein continued. In contrast, expression of C5 mRNA only increased two-fold and was elevated similarly at all weight losses between 7.5 and 27%. Both proteasome functional activity, and proteasome-specific tyrosine release as a measure of total protein degradation was also maximal at 18–20% weight loss and decreased at higher weight loss. Proteasome expression in pectoral muscle followed a different pattern with increases in C2 and C5 and E2(14k) mRNA only being seen at weight losses above 17%, although muscle loss increased progressively with increasing weight loss. These results suggest that activation of the ubiquitin-proteasome pathway plays a major role in protein loss in gastrocnemius muscle, up to 20% weight loss, but that other factors such as depression in protein synthesis may play a more important role at higher weight loss.
format Text
id pubmed-2361629
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23616292009-09-10 Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia Khal, J Wyke, S M Russell, S T Hine, A V Tisdale, M J Br J Cancer Translational Therapeutics Muscle protein degradation is thought to play a major role in muscle atrophy in cancer cachexia. To investigate the importance of the ubiquitin-proteasome pathway, which has been suggested to be the main degradative pathway mediating progressive protein loss in cachexia, the expression of mRNA for proteasome subunits C2 and C5 as well as the ubiquitin-conjugating enzyme, E2(14k), has been determined in gastrocnemius and pectoral muscles of mice bearing the MAC16 adenocarcinoma, using competitive quantitative reverse transcriptase polymerase chain reaction. Protein levels of proteasome subunits and E2(14k) were determined by immunoblotting, to ensure changes in mRNA were reflected in changes in protein expression. Muscle weights correlated linearly with weight loss during the course of the study. There was a good correlation between expression of C2 and E2(14k) mRNA and protein levels in gastrocnemius muscle with increases of 6–8-fold for C2 and two-fold for E2(14k) between 12 and 20% weight loss, followed by a decrease in expression at weight losses of 25–27%, although loss of muscle protein continued. In contrast, expression of C5 mRNA only increased two-fold and was elevated similarly at all weight losses between 7.5 and 27%. Both proteasome functional activity, and proteasome-specific tyrosine release as a measure of total protein degradation was also maximal at 18–20% weight loss and decreased at higher weight loss. Proteasome expression in pectoral muscle followed a different pattern with increases in C2 and C5 and E2(14k) mRNA only being seen at weight losses above 17%, although muscle loss increased progressively with increasing weight loss. These results suggest that activation of the ubiquitin-proteasome pathway plays a major role in protein loss in gastrocnemius muscle, up to 20% weight loss, but that other factors such as depression in protein synthesis may play a more important role at higher weight loss. Nature Publishing Group 2005-10-03 2005-09-06 /pmc/articles/PMC2361629/ /pubmed/16160695 http://dx.doi.org/10.1038/sj.bjc.6602780 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Khal, J
Wyke, S M
Russell, S T
Hine, A V
Tisdale, M J
Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia
title Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia
title_full Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia
title_fullStr Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia
title_full_unstemmed Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia
title_short Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia
title_sort expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361629/
https://www.ncbi.nlm.nih.gov/pubmed/16160695
http://dx.doi.org/10.1038/sj.bjc.6602780
work_keys_str_mv AT khalj expressionoftheubiquitinproteasomepathwayandmusclelossinexperimentalcancercachexia
AT wykesm expressionoftheubiquitinproteasomepathwayandmusclelossinexperimentalcancercachexia
AT russellst expressionoftheubiquitinproteasomepathwayandmusclelossinexperimentalcancercachexia
AT hineav expressionoftheubiquitinproteasomepathwayandmusclelossinexperimentalcancercachexia
AT tisdalemj expressionoftheubiquitinproteasomepathwayandmusclelossinexperimentalcancercachexia